Coal Workers' Pneumoconiosis (Complicated)
Conditions
Keywords
Black Lung, Black Lung Disease, Coal Miner's Lung, Coal Worker's Pneumoconiosis, Coalworker's Pneumoconiosis, Pneumoconiosis, Coal Worker's
Brief summary
Examination of pirfenidone (Esbriet®) therapy in coal workers' pneumoconiosis (black lung) with pulmonary fibrosis (scarring of the lung).
Detailed description
Examination of pirfenidone (Esbriet®) therapy in coal workers' pneumoconiosis with pulmonary fibrosis associated with radiographic and functional impairment to examine the reduction in progression of disease, reduction of exacerbation rates and possible reduction of inflammatory biomarkers as an index of clinical response.
Interventions
DRUGPirfenidone
see previous entries
Sponsors
Genentech, Inc.
Pulmonary Research of Abingdon, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open label interventional study observing US FDA approved Esbriet (for Interstitial Pulmonary Fibrosis) in Coal Workers' Pneumoconiosis patients with pulmonary fibrosis.
Eligibility
Sex/Gender
ALL
Age
40 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Able and willing to provide informed consent and to comply with study protocol * 2\. Coal miners between the ages 40 to 79 years of age at visit 1with a minimum of 15 years in a coal mining environment * 3\. Chest CT Scan or Chest Xray (within 6 months) confirming diagnosis of CWP, complicated black lung disease/progressive massive fibrosis will be recorded. If CT not available must be obtained at Visit 1. * 4\. Evidence of Loss of lung function defined by decline in FEV1 or FVC or DLCO of 5% within the past 36 months prior to enrollment. * 5\. FEV1 ≤ 75% or FVC ≤ 80% or DLCO ≤ 70% or abnormal 6MWT with oxygen desaturation of 4% or greater than resting at screening or within past 6 months. * 6\. Former smokers and current smokers will be enrolled if documented evidence of CWP/PMF is present and meet PFT guidelines. Current smokers will be given smoking cessation counseling at each visit due to the effect on pirfenidone concentration and efficacy.
Exclusion criteria
* 1\. History of prior therapy with Esbriet or Ofev (pirfenidone or nintedanib) * 2\. Recent hospitalization (within 30 days prior to screening) for respiratory decompensation. * 3\. Patients using monoclonal antibody therapy or immunosuppressive therapy for other disease process will be excluded, except for the following: * Daily prednisone up to 10 mg daily (prescribed for lung disease or rheumatoid arthritis) will be permitted. Chronic use for 3 months prior to enrollment will be documented. * Methotrexate for rheumatoid arthritis will be permitted as long as chronic use for 6 months prior to enrollment is documented. * 4\. Elevation of liver function test at screening documenting AST, ALT or total bilirubin \> 3 x ULN or ALP \> 2.5 x ULN. * 5\. Patients who have other pulmonary pathology such as lung cancer, active tuberculosis or atypical mycobacterial infection requiring treatment. * 6\. Patients with recurrent malignancy requiring chemotherapy or radiation therapy. Individuals with a prior diagnosis of localized skin cancer, prostate cancer, localized bladder cancer will not be excluded unless undergoing active treatment. Patients with a prior diagnosis of malignancy treated greater than 5 years ago will be considered for enrollment. * 7\. History of alcohol or drug abuse that would impair or risk the patient's full participation in the drug study in the opinion of the investigator * 8\. Use of any investigational therapy within 4 weeks of enrollment. * 9\. Individuals with clinically significant unstable cardiac disease (ejection fraction ≤35%) or complex arrhythmias per PI discretion. Chronic atrial fibrillation will be permitted if heart rate is controlled. Historical values of ejection fraction will be accepted. * 10\. Individuals with poorly controlled diabetes per PI discretion (Hemoglobin A1c \>9). Historical values will be accepted. * 11\. Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Forced Vital Capacity (FVC) | 12 months minimum | Primary objective for this study is to determine the rate of decline ( relative change in FVC (% and ml) in patients with coal workers' pneumoconiosis (Black Lung) with pulmonary fibrosis (CWP/PMF) during treatment with pirfenidone (Esbriet®). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Inflammatory biomarkers | 12 months minimum | The reduction of inflammatory biomarkers (Interleukin-6 \[IL-6\], Transforming Growth Factor Beta 1 \[TGF-β 1\] and Tumor Necrosis Factor Alpha \[TNF-α\]) and the potential reduction correlation with change in lung function |
| 6 minute walk test | 12 months minimum | rate of decline of 6 minute walk test compared to baseline assessments established at enrollment. |
| Chest CT | 12 months | Chest CT scans will be reviewed to determine if radiographic progression occurs during therapy. |
| Diffusing capacity of the lung for carbon monoxide (DLCO) | 12 months minimum | rate of decline (relative change in %) of DLCO compared to baseline assessments established at enrollment. |
| St. George's Respiratory Questionnaire (SGRQ) | 12 months minimum | Change in total score compared to baseline. Total score summarizes the impact of the disease on overall health status. Scores range from 0 - 100, with higher scores indicating more limitations. |
| Forced Expiratory Volume in 1 second (FEV1) | 12 months minimum | rate of decline (relative change in % and ml )of FEV1 compared to baseline assessments established at enrollment. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Rates of Respiratory Exacerbation | 12 months minimum | Change in exacerbation rate compared to 12 months prior to enrollment, including respiratory-related hospitalizations. |
Countries
United States
Outcome results
None listed